How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results

How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results
Apr 08 2026 10:19 UTC
#pfizer #oncology #ibrance #seagen #adcs #biosimilars #earnings #pipeline
rwatimes.io/articles/qz-how-pfizers-...

US pharma tariffs of up to 100% finalised by Trump Trump signs his pharma tariffs executive order, which won't affect most large pharma groups but could deal a hefty blow to smaller companies.

#pharmaindustry #USpharmatariffs #pharmatariffs #brandedpharmaceuticals #drugpricingdeals #medicineimports #pharmaceuticalimports #APIimports #generics #biosimilars #specialitydrugs #MFNpricing #NHS #UKgovernment #pharmaceuticalexports #PhRMA #MBAA #Alnylam #BioMarin #Exelixis #Incyte
zurl.co/8FBqo

22-23 PHARMA - Fast and the curious This month: the NHS as a dystopian game of Tetris, the GLP-1 explosion and its impact on future meds, plus deep dives into AI in pharma, reproductive health, and Trump’s healthcare influence. Also, co...

#mRNAvaccines #GLP1 #obesity #CARTcelltherapies #oncology #PCSK9inhibitors #HepatitisC #Immunotherapy #checkpointinhibitors #RSVvaccines #Genetherapies #rarediseases #antivirals #Biosimilars #expandedaccess #biologics #HIV #Migraine #CGRPinhibitors #antifungals #precisionmedicine
zurl.co/3UDz7

AEON Biopharma Reports Biosimilar Progress, Secures $3.5M AEON Biopharma on Mar 30, 2026 announced completion of analytical comparability work and a $3.5M financing, targeting an IND filing in Q4 2026 (Investing.com, Mar 30, 2026).

AEON Biopharma Reports Biosimilar Progress, Secures $3.5M: AEON Biopharma on Mar 30, 2026 announced completion of analytical comparability work and a $3.5M financing, targeting an IND filing in Q4… 👈 Read full analysis #Biopharma #Biosimilars #HealthcareInvestment #INDFilings #PharmaceuticalIndustry

Shreehas Tambe Takes the Helm as CEO of Biocon Limited Starting April 1, 2026 Biocon Limited has announced the appointment of Shreehas Tambe as CEO and Managing Director, starting April 1, 2026, to strengthen its global position.

Shreehas Tambe Takes the Helm as CEO of Biocon Limited Starting April 1, 2026 #India #Bengaluru #Biosimilars #Biocon_Limited #Shreehas_Tambe

Biologics and Biosimilars in Dermatology | Docwire News Derm Immuno Today Editorial Board Member Steven Feldman, MD, comments on the current landscape of biologics and biosimilars in dermatology.

Commenting on #biosimilars in #dermatology, Dr Steve Feldman of Wake Forest says, "I don’t think we’ll be able to help more patients, and I think there will be some frustrating hurdles to navigate in this new landscape."

Read the full commentary below!

ACR 2024 Clip with NEW Volunteer Commentary

Yyour insurer might be manufacturing your biosimilar. Think about that. This clip's from "Go With Us!" to ACR 2024. Sign up for our next "Go With Us!" at zurl.co/gZGkw

👉 zurl.co/bs5Rw
🎥 zurl.co/JIS94

#AiArthritis #Biosimilars #PatientAdvocacy

Cytiva and Yosindo Collaborate to Enhance Biosimilar Manufacturing in Japan Cytiva and Yosindo's collaboration aims to establish efficient biosimilar production in Japan, enhancing local supply and technological capabilities.

Cytiva and Yosindo Collaborate to Enhance Biosimilar Manufacturing in Japan #Japan #Biosimilars #Toyama #Cytiva #Yosindo

“Gainsharing” methods of payment can boost use of biosimilars, a less expensive cancer treatment A new study looks at mechanisms that could induce hospitals to switch to less expensive biosimilar treatment alternatives.

New research led by Professor of #HealthEconomics James Robinson highlights how #gainsharing can significantly boost the use of #biosimilars, encouraging providers to choose cost-effective treatments, lowering #healthcare expenses while maintaining high-quality care. https://ow.ly/9Yf450YvCHt

Line graph titled "Figure 2. Line Graph of Trends in Adoption of Biosimilars Over Biologics." Adoption rates from 2020-2024 for Bevacizumab, Rituximab, and Trastuzumab are shown. Bevacizumab has the highest adoption rate, followed by Rituximab and then Trastuzumab.

Declining acquisition prices for #Biosimilars led to higher hospital markup margins and rapid increase in biosimilar adoption for bevacizumab, trastuzumab, and rituximab between 2020 and 2024.

ja.ma/3NkbmAI

Arzneimittelmarkt 2025: Absatz in Apotheken weiter rückläufig Während die Absatzzahlen im Arzneimittelmarkt in 2025 in vielen Bereichen zurückgehen, steigt der Arzneimittelumsatz aufgrund des wachsenden Mark...

Während die Absatzzahlen im #Arzneimittelmarkt in 2025 in vielen Bereichen zurückgehen, steigt der Arzneimittelumsatz aufgrund des wachsenden Marktanteils von #Biologika und #Biosimilars. Das zeigen Zahlen des Dienstleisters IQVIA. Im Bereich #OTC boomt der Versandhandel.

#Apotheken #Medikamente

Line graph titled "Figure 2. Line Graph of Trends in Adoption of Biosimilars Over Biologics". The Y axis shows "Adoption of biosimilar, %" from 0 to 100. The X axis shows "Year" from 2020 to 2024. Three lines show adoption trends for Bevacizumab, Rituximab, and Trastuzumab.

Declining acquisition prices for #Biosimilars led to higher hospital markup margins and rapid increase in biosimilar adoption for bevacizumab, trastuzumab, and rituximab between 2020 and 2024.

ja.ma/47F3dO2

📌 For informational and educational purposes only.

If you think any of the material in this post shouldn't be here, just inform us and we'll act promptly.

#FDA #Biosimilars #DrugPrices #HealthPolicy #karmactive

The #FDA has issued updated #guidance that aims to make it easier for drugmakers to bring #biosimilars of patent-expired #biologicdrugs to market, in the hope of reducing medicine #prices.

pharmaphorum.com/home/fda-cut...

FDA Introduces Revolutionary Biosimilar Guidance Reducing Development Costs Significantly The FDA has released updated guidelines for biosimilar development, which could cut costs by up to 50%, fostering competition in the biotech space.

FDA Introduces Revolutionary Biosimilar Guidance Reducing Development Costs Significantly #United_States #Washington #Biosimilars #FDA_Regulations #Professor_Niazi

" #Biosimilars are the generic equivalents of expensive biologic drugs, offering the same safety and effectiveness as brand-name biologics at significantly lower costs.2 But burdensome regulatory criteria have kept biosimilars from reaching their potential—until now."

Kommentar: Mit Ärger ist zu rechnen Mit den Regeln zur Austauschbarkeit von Biologika in Apotheken, die am 1. April in Kraft treten, haben sich der G-BA und das BMG gegen eine Koalition aus &...

Mit den Regeln zur Austauschbarkeit von #Biologika in #Apotheken, die am 1.4. in Kraft treten, haben sich der G-BA und das BMG gegen eine Koalition aus Ärzte- und Apothekerschaft, Patientenvertretern und den Herstellern von #Biosimilars durchgesetzt. Es ist eine Machtdemonstration der Krankenkassen.

Pharmalot: We're reading about a lack of FDA adcomms, FDA loosening biosimilar rules, and more There is growing concern that the FDA is shunning advisory committees that allow agency leaders, drugmakers, patients, and doctors to speak their minds in public

Pharmalot.. Pharmalittle.. We're reading about: We’re reading about a lack of FDA adcomms, FDA loosening biosimilar rules, and more news.. statnews.com/pharmalot/20... #pharma #FDA #biosimilars #novonordisk #Wegovy #weight #obesity #HIMS

Ab 1. April: Die neuen Austauschregeln für Biologika Biosimilars müssen in der Apotheke künftig unter bestimmten Bedingungen ausgetauscht werden – und zwar nicht nur bei bestehenden Rabattvert...

#Biosimilars müssen in der #Apotheke künftig unter bestimmten Bedingungen ausgetauscht werden – und zwar nicht nur bei bestehenden Rabattverträgen. Ab dem 1. April gelten dieselben Preisvorgaben wie bei Generika. Im Rahmenvertrag sollen bis zum Monatswechsel noch einige Anpassungen umgesetzt werden.

Austausch von Original-Medikamenten – was sich ab 1. April bei Mitteln wie Insulin ändert Ab April 2026 können Apotheken sogenannte Biosimilar statt eines Original-Medikaments herausgeben. Was Patienten über den Austausch von Biologika-Medikamenten wie Insulinen wissen müssen.

Ab April 2026 können #Apotheken sogenannte #Biosimilars statt eines Original-Medikaments herausgeben. Was #Patienten über den Austausch von Biologika wie Insulinen wissen müssen.

SteinCares and Shilpa Biologicals Unite to Enhance Biosimilar Accessibility in Latin America A collaborative licensing agreement between SteinCares and Shilpa Biologicals aims to boost access to biosimilars in Latin America, enhancing treatment availability.

SteinCares and Shilpa Biologicals Unite to Enhance Biosimilar Accessibility in Latin America #San_Jose #Costa_Rica #SteinCares #Biosimilars #Shilpa_Biologicals

SteinCares and Shilpa Biologicals Unite to Improve Biosimilar Access in Latin America SteinCares and Shilpa Biologicals have announced a licensing agreement aimed at enhancing biosimilar accessibility throughout Latin America.

SteinCares and Shilpa Biologicals Unite to Improve Biosimilar Access in Latin America #San_Jose #Costa_Rica #SteinCares #Biosimilars #Shilpa_Biologicals

SteinCares and Shilpa Biologicals Form Strategic Partnership to Expand Biosimilar Access in Latin America SteinCares teams up with Shilpa Biologicals to enhance access to biosimilars across Latin America, aiming to offer affordable treatments to more patients.

SteinCares and Shilpa Biologicals Form Strategic Partnership to Expand Biosimilar Access in Latin America #San_Jose #Costa_Rica #SteinCares #Biosimilars #Shilpa_Biologicals

SteinCares and Shilpa Biologicals Collaborate to Boost Biosimilar Access in Latin America SteinCares and Shilpa Biologicals have formed a strategic partnership to enhance access to biosimilars across Latin America, increasing affordable treatment options for patients.

SteinCares and Shilpa Biologicals Collaborate to Boost Biosimilar Access in Latin America #San_Jose #Costa_Rica #SteinCares #Biosimilars #Shilpa_Biologicals

Understanding Financial Aspects of IBD Through Bio-Medicines and Biosimilars Explore the financial implications of IBD treatments in our upcoming online lecture, focusing on bio-medicines and biosimilars for patients and families.

Understanding Financial Aspects of IBD Through Bio-Medicines and Biosimilars #Japan #IBD #Biosimilars #Kashiwa #Bio-Medicines

Cardinal Health’s New Biosimilars Report: Saving Costs and Enhancing Provider Trust Cardinal Health’s 2026 Biosimilars Report reveals significant cost savings and provider confidence in biosimilars, particularly in oncology.

Cardinal Health’s New Biosimilars Report: Saving Costs and Enhancing Provider Trust #USA #oncology #Dublin #Biosimilars #Cardinal_Health

Immunology 2025 Review: From Mechanism Proliferation to Platform Discipline - LucidQuest Ventures Immunology 2025 Review focused on durable benefit, simplified delivery, and access, with biosimilars and persistence shaping outcomes.

#Immunology in 2025 shifted from novelty to discipline. Platforms, oral and SC delivery, #biosimilars, and access strategy defined success as durability, persistence, and system fit overtook efficacy alone. 👉 Read more: http://dlvr.it/TR1r29 #LucidQuest

Save on Research Grade Biosimilars this spring 🌱

2BScientific is offering 5% off biosimilars from Ichor Bio, AntibodySystem & Absolute Antibody. Ideal tools for preclinical research and drug development.

Find out more: buff.ly/yRMoOns

#ResearchGrade #Biosimilars #LifeSciences

JPM26: What’s in a biopharma? CEO says Teva has the goods In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a leading generics drugmaker. | Under CEO Richard Francis, Teva has long bee...

#JPM26 #biopharma #Teva #TevaPharmaceuticals #RichardFrancis #innovativemedicines #generics #biopharmaidentity #PivottoGrowth #RoyaltyPharma #TEV408 #vitiligo #phase2bstudy #genericmedicines #schizophrenia #olanzapine #Uzedy #longactingmedication #biosimilars #biosimilarmarket
zurl.co/ErF5t

Investigación de mercado de biosimilares de anticuerpos monoclonales de omalizumab: estudio en profundidad hasta 2032 El tamaño del mercado de equipos de venta de farmacias se estimó en 1,7 mil millones de dólares en 2023. Se espera que la industria del mercado de equipos de venta de farmacias crezca de 1,89 mil mill...

Rising biosimilar development is increasing accessibility to omalizumab therapies. #Biosimilars #Biopharma www.wiseguyreports.com/fr/reports/o...